Pulmonary Toxicities of Immunotherapy
Authors:
- Pradnya D. PatilPPPradnya D. Patil
- Tanmay S. PanchabhaiTPTanmay S. Panchabhai
- 1 January 2020
- book chapter
- Published by Elsevier
- p. 243-252
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2018
- Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic RadiotherapyJAMA Oncology, 2018
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working GroupJournal for ImmunoTherapy of Cancer, 2017
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patientsEuropean Respiratory Journal, 2017
- Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung CancerChest, 2017
- Nivolumab induced radiation recall pneumonitis after two years of radiotherapyAnnals of Oncology, 2017
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 TherapyJournal of Clinical Oncology, 2017
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced CancerJAMA Oncology, 2016
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2015
- Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapyJournal of Translational Medicine, 2005